MOUNTAIN VIEW, CA -- (Marketwired) -- 04/25/14 -- Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will release its financial and operating results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.
Chris Lowe, President and Interim Chief Executive Officer, and Peter Mariani, Chief Financial Officer, will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on May 7, 2014 to discuss the company's results. The call may be accessed by dialing 888-846-5003, or 480-629-9856 for international callers, and referencing the participant code 4681413. The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Investor Relations page of the Company's website, www.hansenmedical.com. Please go to the website at least 15 minutes early to register, download and install any necessary audio software.
For those unable to participate in the live broadcast, a replay will be available two hours after the call ends through Wednesday, May 14, 2014, at 877-870-5176 or 858-384-5517 for international callers, access code 4681413. A replay of the call will be archived on the Investor Relations page of the Company's website.
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is a global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan Robotic System, 9Fr Magellan Robotic Catheter, Magellan 6Fr Robotic Catheter, and related accessories are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices. The Magellan 9Fr Robotic Catheter has undergone both CE marking and 510(k) clearance and is commercially available in the European Union, and the U.S. The Magellan 6Fr Robotic Catheter has undergone 510(k) clearance in the U.S. and is in limited release for the next several months in anticipation of more wide-scale commercially availability later in 2014. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan® and Artisan Extend® Control Catheters are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S., the Company's Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheters are cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the U.S., the Sensei X Robotic Catheter System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X Robotic Catheter System and Artisan and Artisan Extend Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.
"Artisan Extend," "Hansen Medical," "Hansen Medical (with Heart Design)," "Heart Design (Logo)," "Sensei," "Lynx," "Artisan," "Instinctive Motion," "Fine Force Technology," "IntelliSense" are registered trademarks, and "Magellan" and "Hansen Medical Magellan" are trademarks of Hansen Medical, Inc. in the U.S. and other countries.